Skip to main content

NEI Archives

Opening a window to glaucoma

Oct. 10, 2022—A metalloprotease enzyme plays an important role in retinal ganglion cell development, Vanderbilt researchers discovered; studying it and other family members may lead to the identification of novel targets for treating glaucoma.

Read more


Mitochondria and retinal degeneration

Aug. 15, 2022—Vanderbilt researchers have developed a new cellular model for exploring mitochondrial dysfunction in age-related macular degeneration, the leading cause of blindness in people over 65.

Read more


New clue to lung scarring

May. 20, 2021—Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases.

Read more


Insights on diabetic retinopathy

Jan. 23, 2020—A drug that targets multiple pathogenic steps in diabetic retinopathy may be an ideal therapeutic strategy for the disease, Vanderbilt researchers report.

Read more


Potassium balance and glaucoma

Jul. 15, 2019—Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma.

Read more


The arrestin-GPCR connection

Apr. 11, 2019—Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.

Read more


Novel methods to treat glaucoma

Nov. 8, 2018—Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.

Read more


Cellular stress defense

Oct. 12, 2018—The modular architecture of small heat-shock proteins contributes to the ability of these proteins to aid cells in responding to stress.

Read more


Aqueous humor, microRNAs and glaucoma

Apr. 10, 2018—New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.

Read more


A cataract-heart connection

Jan. 25, 2018—Studies of alpha-B crystallin in zebrafish could ultimately lead to improved treatment for cataracts and heart disease.

Read more


Cytokine linked to blindness

Jun. 30, 2017—A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.

Read more


Protecting the blood-brain barrier

Dec. 9, 2016—Vanderbilt investigators have discovered how a promising cancer immunotherapy causes brain swelling, findings that could lead to ways to protect brain function while fighting cancers.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more